Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Jul;66(1):139–142. doi: 10.1038/bjc.1992.231

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.

J H Davies 1, M Dowsett 1, S Jacobs 1, R C Coombes 1, A Hedley 1, R J Shearer 1
PMCID: PMC1977910  PMID: 1637664

Abstract

We report the use of the steroidal aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA, CGP 32349), in the management of patients with advanced, hormone resistant, prostatic cancer. Eighteen of 25 patients (72%) showed a subjective response, mainly in the form of pain relief and increased performance. There were no objective improvements. A tumour flare occurred in 17/25 (68%). Detailed endocrine studies were performed during treatment. These showed that suppression of serum oestradiol levels occurred in 19/25 (76%) of patients during treatment with 4-OHA. Serum levels of androstenedione increased in 9/14 patients (64%). Concentration of serum testosterone and 5 alpha-dihydrotestosterone were elevated in 3/14 (21%) and 2/11 (18%) patients respectively. There appeared to be no correlation between response or tumour flare and changes in steroid levels during treatment with 4-OHA. The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer remains obscure. 4-OHA or its metabolites may be acting on metastatic bone metabolism via effects on oestrogen related osteoclastic and osteoblastic activity. Further investigation of the effects of aromatase inhibitors on prostatic biology, and bone metabolism in patients with metastatic prostate cancer, would appear worthwhile.

Full text

PDF
139

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brodie A. M., Garrett W. M., Hendrickson J. R., Tsai-Morris C. H., Marcotte P. A., Robinson C. H. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo. Steroids. 1981 Dec;38(6):693–702. doi: 10.1016/0039-128x(81)90087-8. [DOI] [PubMed] [Google Scholar]
  2. Brodie A. M., Schwarzel W. C., Shaikh A. A., Brodie H. J. The effect of an aromatase inhibitor, 4-hydroxy-4-androstene-3,17-dione, on estrogen-dependent processes in reproduction and breast cancer. Endocrinology. 1977 Jun;100(6):1684–1695. doi: 10.1210/endo-100-6-1684. [DOI] [PubMed] [Google Scholar]
  3. Coombes R. C., Goss P., Dowsett M., Gazet J. C., Brodie A. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet. 1984 Dec 1;2(8414):1237–1239. doi: 10.1016/s0140-6736(84)92795-8. [DOI] [PubMed] [Google Scholar]
  4. Dowsett M., Cunningham D. C., Stein R. C., Evans S., Dehennin L., Hedley A., Coombes R. C. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989 Mar 1;49(5):1306–1312. [PubMed] [Google Scholar]
  5. Dowsett M., Goss P. E., Powles T. J., Hutchinson G., Brodie A. M., Jeffcoate S. L., Coombes R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987 Apr 1;47(7):1957–1961. [PubMed] [Google Scholar]
  6. Dowsett M., Lloyd P. Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men. Cancer Chemother Pharmacol. 1990;27(1):67–71. doi: 10.1007/BF00689279. [DOI] [PubMed] [Google Scholar]
  7. Dowsett M., Shearer R. J., Ponder B. A., Malone P., Jeffcoate S. L. The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients. Br J Cancer. 1988 Feb;57(2):190–192. doi: 10.1038/bjc.1988.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harris A. L., Mitchell M. D., Smith I. E., Powles T. J. Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer. Br J Cancer. 1983 Oct;48(4):595–598. doi: 10.1038/bjc.1983.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Henderson D., Habenicht U. F., Nishino Y., Kerb U., el Etreby M. F. Aromatase inhibitors and benign prostatic hyperplasia. J Steroid Biochem. 1986 Nov;25(5B):867–876. doi: 10.1016/0022-4731(86)90318-3. [DOI] [PubMed] [Google Scholar]
  10. Matzkin H., Braf Z. Endocrine treatment of benign prostatic hypertrophy: current concepts. Urology. 1991 Jan;37(1):1–16. doi: 10.1016/0090-4295(91)80069-j. [DOI] [PubMed] [Google Scholar]
  11. Parker M. C., Cook A., Riddle P. R., Fryatt I., O'Sullivan J., Shearer R. J. Is delayed treatment justified in carcinoma of the prostate? Br J Urol. 1985 Dec;57(6):724–728. doi: 10.1111/j.1464-410x.1985.tb07041.x. [DOI] [PubMed] [Google Scholar]
  12. Ponder B. A., Shearer R. J., Pocock R. D., Miller J., Easton D., Chilvers C. E., Dowsett M., Jeffcoate S. L. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer. 1984 Dec;50(6):757–763. doi: 10.1038/bjc.1984.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Robinson M. R. Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years. Br J Urol. 1980 Aug;52(4):328–329. doi: 10.1111/j.1464-410x.1980.tb08932.x. [DOI] [PubMed] [Google Scholar]
  14. Shearer R. J., Davies J. H., Dowsett M., Malone P. R., Hedley A., Cunningham D., Coombes R. C. Aromatase inhibition in advanced prostatic cancer: preliminary communication. Br J Cancer. 1990 Aug;62(2):275–276. doi: 10.1038/bjc.1990.276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Worgul T. J., Santen R. J., Samojlik E., Veldhuis J. D., Lipton A., Harvey H. A., Drago J. R., Rohner T. J. Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma. J Urol. 1983 Jan;129(1):51–55. doi: 10.1016/s0022-5347(17)51916-3. [DOI] [PubMed] [Google Scholar]
  16. Zoppi S., Cocconi M., Lechuga M. J., Messi E., Zanisi M., Motta M. Antihormonal activities of 5 alpha-reductase and aromatase inhibitors. J Steroid Biochem. 1988 Oct;31(4B):677–683. doi: 10.1016/0022-4731(88)90018-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES